DK2046831T3 - Hidtil ukendte, multivalente immunoglobuliner - Google Patents

Hidtil ukendte, multivalente immunoglobuliner

Info

Publication number
DK2046831T3
DK2046831T3 DK07718518.9T DK07718518T DK2046831T3 DK 2046831 T3 DK2046831 T3 DK 2046831T3 DK 07718518 T DK07718518 T DK 07718518T DK 2046831 T3 DK2046831 T3 DK 2046831T3
Authority
DK
Denmark
Prior art keywords
new multivalent
multivalent immunoglobulins
immunoglobulins
new
multivalent
Prior art date
Application number
DK07718518.9T
Other languages
English (en)
Inventor
Gordana Wozniak-Knopp
Florian Rueker
Gottfried Himmler
Original Assignee
Star Biotechnologische Forschungs Und Entwicklungsges M B H F
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Star Biotechnologische Forschungs Und Entwicklungsges M B H F filed Critical Star Biotechnologische Forschungs Und Entwicklungsges M B H F
Application granted granted Critical
Publication of DK2046831T3 publication Critical patent/DK2046831T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46Hybrid immunoglobulins
    • C07K16/468Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/005Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK07718518.9T 2006-07-05 2007-06-26 Hidtil ukendte, multivalente immunoglobuliner DK2046831T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT0114706A AT503889B1 (de) 2006-07-05 2006-07-05 Multivalente immunglobuline
PCT/AT2007/000313 WO2008003103A2 (en) 2006-07-05 2007-06-26 Novel multivalent immunoglobulins

Publications (1)

Publication Number Publication Date
DK2046831T3 true DK2046831T3 (da) 2012-05-29

Family

ID=38720179

Family Applications (2)

Application Number Title Priority Date Filing Date
DK11194316.3T DK2463302T3 (da) 2006-07-05 2007-06-26 Multivalente immunglobuliner modificeret i den strukturelle loop-region
DK07718518.9T DK2046831T3 (da) 2006-07-05 2007-06-26 Hidtil ukendte, multivalente immunoglobuliner

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK11194316.3T DK2463302T3 (da) 2006-07-05 2007-06-26 Multivalente immunglobuliner modificeret i den strukturelle loop-region

Country Status (12)

Country Link
US (3) US20100048877A1 (da)
EP (2) EP2463302B1 (da)
JP (3) JP5924751B2 (da)
CN (3) CN110078828A (da)
AT (2) AT503889B1 (da)
DK (2) DK2463302T3 (da)
ES (2) ES2380127T3 (da)
HU (1) HUE025035T2 (da)
PL (2) PL2046831T3 (da)
PT (2) PT2046831E (da)
SI (2) SI2463302T1 (da)
WO (1) WO2008003103A2 (da)

Families Citing this family (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3261856B2 (ja) 1994-04-12 2002-03-04 東レ株式会社 溶融紡糸方法
US20090298195A1 (en) 2005-01-05 2009-12-03 F-Star Biotechnologische Forschungs-Und Entwicklun Gseges M.B.H. Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
AT503889B1 (de) 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F Multivalente immunglobuline
AT503902B1 (de) * 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von immunglobulinen
CN103897063B (zh) 2007-06-01 2017-04-12 马里兰大学巴尔的摩分校 免疫球蛋白恒定区Fc受体结合剂
PL3241842T3 (pl) 2007-06-26 2024-06-10 F-Star Therapeutics Limited Prezentacja środków wiążących
US8629246B2 (en) 2007-09-26 2014-01-14 Ucb Pharma S.A. Dual specificity antibody fusions
US8557242B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute ERBB2 antibodies comprising modular recognition domains
US8557243B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute EFGR antibodies comprising modular recognition domains
US8454960B2 (en) 2008-01-03 2013-06-04 The Scripps Research Institute Multispecific antibody targeting and multivalency through modular recognition domains
KR101658247B1 (ko) 2008-01-03 2016-09-22 더 스크립스 리서치 인스티튜트 모듈 인식 도메인을 통한 항체 표적화
US8574577B2 (en) 2008-01-03 2013-11-05 The Scripps Research Institute VEGF antibodies comprising modular recognition domains
JP5889533B2 (ja) * 2008-01-31 2016-03-22 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ 改変された抗体定常ドメイン分子
EP2113255A1 (en) * 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Cytotoxic immunoglobulin
WO2010035012A1 (en) 2008-09-26 2010-04-01 Ucb Pharma S.A. Biological products
EP2451838A1 (en) * 2009-07-09 2012-05-16 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Stabilized immunoglobulin constant domains
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
EP2407487A1 (en) 2010-07-14 2012-01-18 F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. Multispecific modular antibody
WO2012009705A1 (en) 2010-07-15 2012-01-19 Zyngenia, Inc. Ang-2 binding complexes and uses thereof
EP3543257A1 (en) 2010-07-28 2019-09-25 Gliknik Inc. Fusion proteins of natural human protein fragments to create orderly multimerized immunoglobulin fc compositions
CA2806252C (en) 2010-07-29 2019-05-14 Xencor, Inc. Antibodies with modified isoelectric points
US20130273055A1 (en) 2010-11-16 2013-10-17 Eric Borges Agents and methods for treating diseases that correlate with bcma expression
US9156917B2 (en) 2011-02-11 2015-10-13 Research Corporation Technologies, Inc. CH2 domain template molecules derived from rational grafting of donor loops onto CH2 scaffolds
EP2714738B1 (en) 2011-05-24 2018-10-10 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
JP5997151B2 (ja) 2011-06-30 2016-09-28 中外製薬株式会社 ヘテロ二量化ポリペプチド
EP2546268A1 (en) 2011-07-13 2013-01-16 F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. Internalising immunoglobulin
EP3321286B1 (en) * 2011-08-23 2021-01-06 Roche Glycart AG Bispecific t cell activating antigen binding molecules
US12466897B2 (en) 2011-10-10 2025-11-11 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
US20140370012A1 (en) * 2012-01-27 2014-12-18 Gliknik Inc. Fusion proteins comprising igg2 hinge domains
EP4310191A3 (en) * 2012-06-14 2024-05-15 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule containing modified fc region
KR20150058236A (ko) 2012-08-20 2015-05-28 글리크닉 인코포레이티드 항원 결합 및 다가 fc 감마 수용체 결합 활성을 가진 분자
US10766960B2 (en) 2012-12-27 2020-09-08 Chugai Seiyaku Kabushiki Kaisha Heterodimerized polypeptide
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
CA2898100C (en) 2013-01-14 2023-10-10 Xencor, Inc. Novel heterodimeric proteins
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
CA2897987A1 (en) 2013-01-15 2014-07-24 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
US10519242B2 (en) 2013-03-15 2019-12-31 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
MX2015013163A (es) 2013-03-15 2016-04-04 Zyngenia Inc Complejos multiespecificos multivalente y monovalentes y sus usos.
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
EP2970486B1 (en) 2013-03-15 2018-05-16 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
TWI652279B (zh) 2013-11-11 2019-03-01 中外製藥股份有限公司 含改變的抗體可變區之抗原結合分子
JP6775422B2 (ja) 2014-03-28 2020-10-28 ゼンコー・インコーポレイテッドXencor、 Inc. Cd38及びcd3に結合する二重特異性抗体
SG10201913680PA (en) 2014-05-29 2020-03-30 Macrogenics Inc Tri-specific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
DK3180363T3 (da) 2014-08-15 2019-11-04 Merck Patent Gmbh Sirp-alpha-immunoglobulin fusionsproteiner
AP2017009823A0 (en) 2014-09-26 2017-03-31 Macrogenics Inc Bi-specific monovalent diabodies that are capable of binding cd19 and cd3, and uses thereof
EP4632120A3 (en) 2014-11-11 2026-01-07 Chugai Seiyaku Kabushiki Kaisha Library of antigen-binding molecules including modified antibody variable region
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
JP2017536830A (ja) 2014-11-26 2017-12-14 ゼンコー・インコーポレイテッドXencor、 Inc. Cd3及びcd38に結合するヘテロ二量体抗体
SG11201704283PA (en) 2014-11-26 2017-06-29 Xencor Inc Heterodimeric antibodies that bind cd3 and tumor antigens
JP6904902B2 (ja) * 2014-12-05 2021-07-21 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung ドメイン交換抗体
WO2016105450A2 (en) 2014-12-22 2016-06-30 Xencor, Inc. Trispecific antibodies
HK1247215A1 (zh) 2015-01-26 2018-09-21 Macrogenics, Inc. 包含dr5-结合结构域的多价分子
US10227411B2 (en) 2015-03-05 2019-03-12 Xencor, Inc. Modulation of T cells with bispecific antibodies and FC fusions
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
SI3325011T1 (sl) 2015-07-24 2021-02-26 Gliknik Inc. Fuzijski proteini humanih proteinskih fragmentov za tvorbo pravilnih multimeriziranih imunoglobulin FC sestavkov s povečanim vezanjem komplementa
AU2016298227B9 (en) 2015-07-30 2019-10-31 Macrogenics, Inc. PD-1-binding molecules and methods of use thereof
CN108136010A (zh) 2015-10-08 2018-06-08 宏观基因有限公司 用于治疗癌症的联合疗法
JP7058219B2 (ja) 2015-12-07 2022-04-21 ゼンコア インコーポレイテッド Cd3及びpsmaに結合するヘテロ二量体抗体
JP6955507B2 (ja) 2015-12-14 2021-10-27 マクロジェニクス,インコーポレーテッド Pd‐1及びctla‐4との免疫応答性を有する二重特異性並びにその使用方法
TW201730212A (zh) 2016-02-17 2017-09-01 宏觀基因股份有限公司 Ror1-結合分子及其使用方法
CA3020864A1 (en) 2016-04-15 2017-10-19 Macrogenics, Inc. Novel b7-h3-binding molecules, antibody drug conjugates thereof and methods of use thereof
GB2550114A (en) 2016-05-03 2017-11-15 Kymab Ltd Methods, regimens, combinations & antagonists
CA3026420A1 (en) 2016-06-07 2017-12-14 Gliknik Inc. Cysteine-optimized stradomers
MA45255A (fr) 2016-06-14 2019-04-17 Xencor Inc Anticorps inhibiteurs de points de contrôle bispécifiques
JP7461741B2 (ja) 2016-06-20 2024-04-04 カイマブ・リミテッド 抗pd-l1およびil-2サイトカイン
BR112018076525A2 (pt) 2016-06-20 2019-04-02 F-Star Beta Limited membros de ligação a lag-3
KR20190020341A (ko) 2016-06-28 2019-02-28 젠코어 인코포레이티드 소마토스타틴 수용체 2에 결합하는 이종이량체 항체
CA3032897A1 (en) 2016-08-09 2018-02-15 Kymab Limited Anti-icos antibodies
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
BR112019007281A2 (pt) 2016-10-14 2019-07-09 Xencor Inc proteína heterodimérica, composições de ácido nucleico e de vetor de expressão, vetor de expressão, célula hospedeira, e, métodos para produzir proteína heterodimérica e para tratar câncer em um paciente
IL266988B2 (en) 2016-12-09 2024-11-01 Gliknik Inc Methods of treating inflammatory disorders with multivalent fc compounds
EP3551647A4 (en) 2016-12-09 2021-01-13 Gliknik Inc. MANUFACTURING OPTIMIZATION OF GL-2045, A MULTIMERIZING STRADOMER
AU2017382234B2 (en) 2016-12-23 2025-01-30 Macrogenics, Inc. ADAM9-binding molecules, and methods of use thereof
WO2018138297A1 (en) 2017-01-27 2018-08-02 Kymab Limited Anti-opg antibodies
NZ756763A (en) 2017-02-17 2023-04-28 Denali Therapeutics Inc Engineered transferrin receptor binding polypeptides
JP7132232B2 (ja) 2017-02-24 2022-09-06 マクロジェニクス,インコーポレーテッド Cd137及び腫瘍抗原に結合できる二重特異性結合分子並びにその使用
ES3063092T3 (en) 2017-06-14 2026-04-15 Kymab Ltd Use of the extracellular domain of the transferrin receptor 2 for diagnosis and treatment of primary and secondary sclerosing diseases
GB201709970D0 (en) 2017-06-22 2017-08-09 Kymab Ltd Bispecific antigen-binding molecules
AU2018291497A1 (en) 2017-06-30 2020-01-16 Xencor, Inc. Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15Ra and antigen binding domains
JP6598344B2 (ja) 2017-07-31 2019-10-30 国立大学法人 東京大学 環状ペプチドをタンパク質構造に提示させる超汎用法
MX2020002918A (es) 2017-10-02 2020-07-22 Denali Therapeutics Inc Proteinas de fusion que comprenden enzimas de terapia de reemplazo de enzimas.
AU2018366199A1 (en) 2017-11-08 2020-05-28 Xencor, Inc. Bispecific and monospecific antibodies using novel anti-PD-1 sequences
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
EP3720963A4 (en) 2017-12-05 2021-12-08 Chugai Seiyaku Kabushiki Kaisha ANTIGEN-BINDING MOLECULE WITH CHANGED BINDING OF THE VARIABLE ANTIBODY REGIONS CD3 AND CD137
JP2021505637A (ja) 2017-12-12 2021-02-18 マクロジェニクス,インコーポレーテッド 二重特異性cd16結合分子、及び疾患の治療におけるその使用
AU2018390418B2 (en) 2017-12-19 2023-12-21 Xencor, Inc. Engineered IL-2 Fc fusion proteins
EP3728314A1 (en) 2017-12-19 2020-10-28 Kymab Limited Bispecific antibody for icos and pd-l1
GB201721338D0 (en) 2017-12-19 2018-01-31 Kymab Ltd Anti-icos Antibodies
SG11202007572VA (en) 2018-02-15 2020-09-29 Macrogenics Inc Variant cd3-binding domains and their use in combination therapies for the treatment of disease
AU2019247415A1 (en) 2018-04-04 2020-10-22 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
US10654944B2 (en) 2018-04-10 2020-05-19 Y-Biologics Inc. Cell engaging binding molecules
CA3097593A1 (en) 2018-04-18 2019-10-24 Xencor, Inc. Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
JP2021520829A (ja) 2018-04-18 2021-08-26 ゼンコア インコーポレイテッド IL−15/IL−15RA Fc融合タンパク質およびTIM−3抗原結合ドメインを含む、TIM−3標的化ヘテロ二量体融合タンパク質
WO2019238713A2 (en) 2018-06-13 2019-12-19 Kymab Limited Treatments etc
GB201811403D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Antibody molecules
GB201811404D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-CD137 Antibodies
GB201811410D0 (en) * 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
PL3820569T3 (pl) 2018-07-12 2025-07-14 Invox Pharma Limited Cząsteczki przeciwciał, które wiążą PD-L1 oraz CD137
GB201811415D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-Mesothelin Anti bodies
GB201811408D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd CD137 Binding Molecules
GB201811450D0 (en) 2018-07-12 2018-08-29 F Star Delta Ltd Mesothelin and CD137 binding molecules
AU2019301206B2 (en) 2018-07-12 2025-10-30 Invox Pharma Limited Antibody molecules that bind CD137 and OX40
GB201815629D0 (en) 2018-09-25 2018-11-07 Kymab Ltd Antagonists
SG11202103192RA (en) 2018-10-03 2021-04-29 Xencor Inc Il-12 heterodimeric fc-fusion proteins
GB201820687D0 (en) 2018-12-19 2019-01-30 Kymab Ltd Antagonists
MA54601A (fr) 2018-12-24 2022-03-30 Sanofi Sa Nouvelles protéines de liaison multi-spécifiques à base de pseudofab
WO2020180726A1 (en) 2019-03-01 2020-09-10 Xencor, Inc. Heterodimeric antibodies that bind enpp3 and cd3
GB201905552D0 (en) 2019-04-18 2019-06-05 Kymab Ltd Antagonists
CA3173587A1 (en) 2020-03-31 2021-10-07 Chugai Seiyaku Kabushiki-Kaisha Dll3-targeting multispecific antigen-binding molecules and uses thereof
WO2021231976A1 (en) 2020-05-14 2021-11-18 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
GB202007099D0 (en) 2020-05-14 2020-07-01 Kymab Ltd Tumour biomarkers for immunotherapy
EP4175650A1 (en) 2020-07-06 2023-05-10 Kiromic BioPharma, Inc. Mesothelin isoform binding molecules and chimeric pd1 receptor molecules, cells containing the same and uses thereof
CA3192204A1 (en) 2020-08-19 2022-02-24 Xencor, Inc. Anti-cd28 and/or anti-b7h3 compositions
GB202017058D0 (en) 2020-10-27 2020-12-09 Kymab Ltd Antibodies and uses thereof
WO2022108627A1 (en) 2020-11-18 2022-05-27 Kiromic Biopharma, Inc.Kiromic Biopharma, Inc. Gamma-delta t cell manufacturing processes and chimeric pd1 receptor molecules
GB202101125D0 (en) 2021-01-27 2021-03-10 Kymab Ltd Antibodies and uses thereof
KR20230156079A (ko) 2021-03-09 2023-11-13 젠코어 인코포레이티드 Cd3과 cldn6에 결합하는 이종이량체 항체
US11859012B2 (en) 2021-03-10 2024-01-02 Xencor, Inc. Heterodimeric antibodies that bind CD3 and GPC3
TW202309101A (zh) * 2021-04-19 2023-03-01 美商健生生物科技公司 具有經工程改造之抗體恆定區變體之分子
GB202107372D0 (en) 2021-05-24 2021-07-07 Petmedix Ltd Animal models and therapeutics molecules
GB202209247D0 (en) 2022-06-23 2022-08-10 Petmedix Ltd Animal models and therapeutic molecules
GB202217978D0 (en) 2022-11-30 2023-01-11 Petmedix Ltd Rodents expressing a common light chain
WO2024133161A1 (en) 2022-12-19 2024-06-27 Astrazeneca Ab Treatment of autoimmune disease
CN120813375A (zh) 2023-01-30 2025-10-17 凯玛布有限公司 抗体

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE570027T1 (de) 1984-03-01 1994-11-17 Univ Leland Stanford Junior T-Zellenrezeptor, spezifisch für Antigenpolypeptide und verwandte Polynukleotide.
US6492107B1 (en) 1986-11-20 2002-12-10 Stuart Kauffman Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
DE3546807C2 (da) * 1985-03-30 1991-03-28 Marc Genf/Geneve Ch Ballivet
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
DE69028713T3 (de) * 1989-12-27 2004-05-13 Centocor, Inc. Schimäre immunoglobuline für cd4-rezeptoren
JP3283041B2 (ja) * 1990-07-13 2002-05-20 学校法人藤田学園 人工抗体
ES2113940T3 (es) 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
AU662148B2 (en) 1991-04-10 1995-08-24 Scripps Research Institute, The Heterodimeric receptor libraries using phagemids
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
US5395750A (en) 1992-02-28 1995-03-07 Hoffmann-La Roche Inc. Methods for producing proteins which bind to predetermined antigens
AU675223B2 (en) 1992-05-08 1997-01-30 Creative Biomolecules, Inc. Chimeric multivalent protein analogues and methods of use thereof
EP0672068A4 (en) 1992-09-25 1997-02-26 Commw Scient Ind Res Org TARGET MOLECULES BINDING POLYPEPTIDES.
US5536814A (en) * 1993-09-27 1996-07-16 La Jolla Cancer Research Foundation Integrin-binding peptides
CA2190101A1 (en) * 1994-05-13 1995-11-23 Donald Leonard Nicholas Cardy Improvements in or relating to peptide delivery
GB9501079D0 (en) 1995-01-19 1995-03-08 Bioinvent Int Ab Activation of T-cells
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
US5783186A (en) 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
US6361974B1 (en) * 1995-12-07 2002-03-26 Diversa Corporation Exonuclease-mediated nucleic acid reassembly in directed evolution
US6358709B1 (en) 1995-12-07 2002-03-19 Diversa Corporation End selection in directed evolution
US6352842B1 (en) 1995-12-07 2002-03-05 Diversa Corporation Exonucease-mediated gene assembly in directed evolution
ATE279947T1 (de) 1996-03-18 2004-11-15 Univ Texas Immunglobulinähnliche domäne mit erhöhten halbwertszeiten
US6696251B1 (en) 1996-05-31 2004-02-24 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
EP0977886A4 (en) 1997-03-07 2002-10-23 Sunol Molecular Corp FUSION PROTEINS, WHICH CONTAIN A BACTERIOPHAGE ENVELOPE PROTEIN AND A SINGLE CHAIN T-CELL RECEPTOR
US6057098A (en) 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries
JP3614866B2 (ja) 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ,インコーポレイティド 人工抗体ポリペプチド
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
AU3657899A (en) 1998-04-20 1999-11-08 James E. Bailey Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
US6180343B1 (en) 1998-10-08 2001-01-30 Rigel Pharmaceuticals, Inc. Green fluorescent protein fusions with random peptides
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
WO2000042560A2 (en) 1999-01-19 2000-07-20 Maxygen, Inc. Methods for making character strings, polynucleotides and polypeptides
US6376246B1 (en) * 1999-02-05 2002-04-23 Maxygen, Inc. Oligonucleotide mediated nucleic acid recombination
CA2362737A1 (en) * 1999-03-05 2000-09-08 Maxygen, Inc. Recombination of insertion modified nucleic acids
US6472147B1 (en) 1999-05-25 2002-10-29 The Scripps Research Institute Methods for display of heterodimeric proteins on filamentous phage using pVII and pIX, compositions, vectors and combinatorial libraries
WO2001001748A2 (en) 1999-07-02 2001-01-11 Genentech, Inc. Peptide compounds that bind her2
AU5076301A (en) 1999-12-06 2001-07-09 Board Of Trustees Of The University Of Illinois, The High affinity tcr proteins and methods
EP1118661A1 (en) 2000-01-13 2001-07-25 Het Nederlands Kanker Instituut T cell receptor libraries
JP2003274960A (ja) 2000-02-03 2003-09-30 Japan Science & Technology Corp 可溶性t細胞受容体タンパク質およびその作成方法
EP1259601A2 (en) 2000-02-22 2002-11-27 Ahuva Nissim Chimeric and tcr phage display libraries, chimeric and tcr reagents and methods of use thereof
AU2001243670A1 (en) 2000-03-20 2001-10-03 Maxygen, Inc. Method for generating recombinant dna molecules in complex mixtures
AU5943201A (en) * 2000-05-03 2001-11-12 Amgen Inc Modified peptides as therapeutic agents
AU2001261628A1 (en) 2000-05-16 2001-11-26 Euroceltique S.A. Cd28 synthebody for the modulation of immune responses
AU2001264946A1 (en) 2000-05-24 2001-12-03 Imclone Systems Incorporated Bispecific immunoglobulin-like antigen binding proteins and method of production
US6406863B1 (en) 2000-06-23 2002-06-18 Genetastix Corporation High throughput generation and screening of fully human antibody repertoire in yeast
AU2001273559A1 (en) 2000-07-18 2002-01-30 Enchira Biotechnology Corporation Methods of ligation mediated chimeragenesis utilizing populations of scaffold and donor nucleic acids
AU2001283496A1 (en) * 2000-07-25 2002-02-05 Immunomedics, Inc. Multivalent target binding protein
JP2002058479A (ja) 2000-08-14 2002-02-26 Canon Inc 構造認識アミノ酸配列の取得方法
EP2141243A3 (en) * 2000-10-16 2010-01-27 Brystol-Myers Squibb Company Protein scaffolds for antibody mimics and other binding proteins
EP1341812A2 (en) 2000-11-08 2003-09-10 Incyte Genomics, Inc. Secreted proteins
GB0029407D0 (en) 2000-12-01 2001-01-17 Affitech As Product
JP4336498B2 (ja) 2000-12-12 2009-09-30 メディミューン,エルエルシー 延長した半減期を有する分子ならびにその組成物および用途
DK1409646T3 (da) 2000-12-19 2012-08-06 Altor Bioscience Corp Transgene dyr omfattende et humaniseret immunsystem
IL141539A0 (en) 2001-02-20 2002-03-10 Yeda Res & Dev Dna molecules and cells transfected therewith
JP4369662B2 (ja) 2001-04-26 2009-11-25 アビディア インコーポレイテッド 単量体ドメインのコンビナトリアルライブラリー
US20030157561A1 (en) 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
EP1281757A1 (en) 2001-07-31 2003-02-05 Direvo Biotech AG Method for the production of nucleic acids consisting of stochastically combined parts of source nucleic acids
MXPA04001974A (es) 2001-08-31 2004-07-16 Avidex Ltd Receptor de celula t soluble.
WO2003029456A1 (en) 2001-10-01 2003-04-10 Dyax Corp. Multi-chain eukaryotic display vectors and uses thereof
ES2384235T3 (es) * 2001-10-22 2012-07-02 The Scripps Research Institute Compuestos dirigidos a integrinas
US20040043424A1 (en) 2001-11-15 2004-03-04 Baughn Mariah R Immunoglobulin superfamily proteins
US20050069549A1 (en) * 2002-01-14 2005-03-31 William Herman Targeted ligands
US20040063924A1 (en) 2002-01-28 2004-04-01 Y Tom Tang Secreted proteins
US20030157091A1 (en) 2002-02-14 2003-08-21 Dyax Corporation Multi-functional proteins
WO2003070190A2 (en) 2002-02-19 2003-08-28 Syntherica Corporation Surrogate antibodies and methods of preparation and use thereof
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US7498414B2 (en) 2002-03-04 2009-03-03 Imclone Systems Incorporated Human antibodies specific to KDR and uses thereof
US20040097711A1 (en) 2002-03-12 2004-05-20 Henry Yue Immunoglobulin superfamily proteins
EP1394251A1 (en) 2002-08-23 2004-03-03 Direvo Biotech AG Method for the selective randomization of polynucleotides
NZ539225A (en) 2002-10-09 2006-09-29 Avidex Ltd Single chain recombinant T cell receptors
EP2284192A3 (en) 2002-11-08 2011-07-20 Ablynx N.V. Camelidae antibodies for sublingual administration
AU2003276403B2 (en) 2002-11-09 2010-04-15 Adaptimmune Limited T cell receptor display
EP1567553A2 (en) 2002-12-03 2005-08-31 Avidex Ltd. Complexes of receptors
GB0304068D0 (en) 2003-02-22 2003-03-26 Avidex Ltd Substances
US20050033029A1 (en) * 2003-06-30 2005-02-10 Jin Lu Engineered anti-target immunoglobulin derived proteins, compositions, methods and uses
WO2005021595A1 (en) 2003-08-28 2005-03-10 Euro-Celtique S.A. Methods of antibody engineering using antibody display rules
WO2005070966A2 (en) * 2004-01-16 2005-08-04 Regeneron Pharmaceuticals, Inc. Fusion polypeptides capable of activating receptors
WO2005092925A2 (en) 2004-03-24 2005-10-06 Xencor, Inc. Immunoglobulin variants outside the fc region
US7785903B2 (en) * 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
EP1756278B1 (en) 2004-05-19 2008-09-17 MediGene Ltd. Method of improving t cell receptors
JP4773434B2 (ja) 2004-05-19 2011-09-14 イムノコア リミテッド 高親和性ny−esot細胞受容体
GB0411773D0 (en) 2004-05-26 2004-06-30 Avidex Ltd Method for the identification of polypeptides which bind to a given peptide mhc complex or cd 1-antigen complex
HRP20141111T1 (hr) 2004-07-22 2015-01-02 Genentech, Inc. Sastav her2-protutijela
US7442778B2 (en) * 2004-09-24 2008-10-28 Amgen Inc. Modified Fc molecules
JP2008514685A (ja) 2004-10-01 2008-05-08 メディジーン リミテッド 治療剤に連結した、非天然型ジスルフィド鎖間結合を含有するt細胞レセプター
WO2007024249A2 (en) 2004-11-10 2007-03-01 Macrogenics, Inc. Engineering fc antibody regions to confer effector function
JP2008520227A (ja) 2004-11-18 2008-06-19 メディジーン リミテッド 可溶性二官能性タンパク質
GB0425732D0 (en) 2004-11-23 2004-12-22 Avidex Ltd Gamma-delta t cell receptors
US20090298195A1 (en) * 2005-01-05 2009-12-03 F-Star Biotechnologische Forschungs-Und Entwicklun Gseges M.B.H. Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
GB0503546D0 (en) 2005-02-21 2005-03-30 Hellenic Pasteur Inst Antibody
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
JP2009538273A (ja) * 2006-04-14 2009-11-05 トルビオン ファーマシューティカルズ, インコーポレイテッド 改造されたFCエフェクター機能を持つ、免疫グロブリン・ヒンジ領域とFc領域とを備える結合タンパク質
AT503889B1 (de) 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F Multivalente immunglobuline
AT503902B1 (de) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von immunglobulinen
EP1975178A1 (en) 2007-03-30 2008-10-01 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Transcytotic modular antibody
PL3241842T3 (pl) 2007-06-26 2024-06-10 F-Star Therapeutics Limited Prezentacja środków wiążących
JP5889533B2 (ja) 2008-01-31 2016-03-22 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ 改変された抗体定常ドメイン分子
EP2113255A1 (en) 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Cytotoxic immunoglobulin
EP2451838A1 (en) 2009-07-09 2012-05-16 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Stabilized immunoglobulin constant domains
US20120010388A1 (en) 2010-04-16 2012-01-12 Gottfried Himmler LeY SPECIFIC BIOTHERAPEUTIC
EP2407487A1 (en) 2010-07-14 2012-01-18 F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. Multispecific modular antibody
US20140087957A1 (en) 2012-09-25 2014-03-27 Marko Vuskovic Methods, assays and kits for cancer diagnosis and screening utilizing glycan-binding and glycan epitopes
GB201317622D0 (en) 2013-10-04 2013-11-20 Star Biotechnology Ltd F Cancer biomarkers and uses thereof

Also Published As

Publication number Publication date
CN101522712A (zh) 2009-09-02
WO2008003103A2 (en) 2008-01-10
DK2463302T3 (da) 2015-06-15
US20180051095A1 (en) 2018-02-22
EP2463302A1 (en) 2012-06-13
ES2539593T3 (es) 2015-07-02
AT503889A1 (de) 2008-01-15
EP2463302B1 (en) 2015-04-01
US11827720B2 (en) 2023-11-28
EP2046831B1 (en) 2012-01-04
PL2046831T3 (pl) 2012-06-29
JP2017163998A (ja) 2017-09-21
PL2463302T3 (pl) 2015-08-31
SI2046831T1 (sl) 2012-03-30
US20100048877A1 (en) 2010-02-25
CN110078828A (zh) 2019-08-02
JP2013240338A (ja) 2013-12-05
JP6215603B2 (ja) 2017-10-18
CN110041430A (zh) 2019-07-23
ATE540056T1 (de) 2012-01-15
AT503889B1 (de) 2011-12-15
WO2008003103A3 (en) 2008-04-17
US20240150495A1 (en) 2024-05-09
HUE025035T2 (en) 2016-01-28
PT2046831E (pt) 2012-04-24
ES2380127T3 (es) 2012-05-08
EP2046831A2 (en) 2009-04-15
JP6681855B2 (ja) 2020-04-15
SI2463302T1 (sl) 2015-08-31
PT2463302E (pt) 2015-07-21
JP2009540837A (ja) 2009-11-26
JP5924751B2 (ja) 2016-05-25

Similar Documents

Publication Publication Date Title
ATE513831T1 (de) Pyridinä3,4-büpyrazinone
HRP20151058T1 (xx) Ariloazol-2-il-cijanoetilamino-spojevi, postupak njihove proizvodnje i postupak njihove uporabe
FR2909857B1 (fr) Endovalve.
BRPI0814466A2 (pt) Método.
BRPI0807991A2 (pt) Anticorpos anti-il-23r elaborados.
CR10161A (es) Inmunoglobulinas
ATE469145T1 (de) 4-ä5-methoxy-6-(2-methyl-6-ä1,2,4ütriazol-1-yl-
NL2000537A1 (nl) Aminederivaten.
BRPI0816970A2 (pt) 1,3-dissubstituídas-4-fenil-1h-piridin-2-onas
SI2046831T1 (sl) Novi multivalentni imunoglobulini
DK2205562T3 (da) 1,1,1-trifluor-2-hydroxy-3-phenylpropanderivater
CR10353A (es) Nuevos compuestos.
DE602007001681D1 (de) 1,3-dioxan-carboxylsäuren
EP2023715A4 (en) Indoleamine-2,3-dioxygenase 2
FI20065446A0 (fi) Muodostusosa
ATE519751T1 (de) Dihydro-benzoäbüä1,4üdiazepin-2-on- sulfonamidderivate
ITCE20060002A1 (it) Patok.
FI20065196A0 (fi) Muodostusosa
FR2898022B1 (fr) Parapluie a egouttoir.
ITPA20060003U1 (it) Bigodino.
ES1062074Y (es) Autorefrigerante solar-ecologico.
ES1061980Y (es) Contenedor-palet.
ITSS20060011A1 (it) Posablocchi.
ITPA20060034A1 (it) Kapot forbir.
ITPA20060014A1 (it) Rubino - macrotex.